Ipsen : CheckMate9ER trial Cabometyx+Opdivo: promising data – TP target price increased: € 100 vs € 91
>Interesting efficacy and survival data - At the ESMO (European Society for Medical Oncology) conference, Ipsen announced the results of its phase III CheckMate 9ER pivotal trial in which Cabometyx® (cabozantinib) in combination with BMS’s Opdivo® (nivolumab) showed significant improvements across all the efficacy endpoints (in particular overall survival) in patients with previously untreated advanced renal cell carcinoma (RCC). The trial was a randomised, multinatio...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.